Full View

Fibrinogen-mimicking, multiarm nanovesicles for human thrombus-specific delivery of tissue plasminogen activator and targeted thrombolytic therapy

Y Huang, B Gu, II Salles-Crawley, KA Taylor, L Yu… - Science …, 2021 - science.org
Clinical use of tissue plasminogen activator (tPA) in thrombolytic therapy is limited by its
short circulation time and hemorrhagic side effects. Inspired by fibrinogen binding to …
被引用次数：41 相关文章

Fibrinogen-mimicking, multiarm nanovesicles for human thrombus-specific delivery of tissue plasminogen activator and targeted thrombolytic therapy.

Y Huang, B Gu, II Salles-Crawley, KA Taylor… - Science …, 2021 - europepmc.org
Clinical use of tissue plasminogen activator (tPA) in thrombolytic therapy is limited by its
short circulation time and hemorrhagic side effects. Inspired by fibrinogen binding to …

[引用][C] Fibrinogen-mimicking, multiarm nanovesicles for human thrombus-specific delivery of tissue plasminogen activator and targeted thrombolytic therapy

Y Huang, B Gu, II Salles-Crawley… - Science …, 2021 - ui.adsabs.harvard.edu
Fibrinogen-mimicking, multiarm nanovesicles for human thrombus-specific delivery of tissue
plasminogen activator and targeted thrombolytic therapy - NASA/ADS Now on home page ads …

Fibrinogen-mimicking, multiarm nanovesicles for human thrombus-specific delivery of tissue plasminogen activator and targeted thrombolytic therapy

Y Huang, B Gu, II Salles-Crawley, KA Taylor, L Yu… - Sci …, 2021 - openaccess.sgul.ac.uk
Clinical use of tissue plasminogen activator (tPA) in thrombolytic therapy is limited by its
short circulation time and hemorrhagic side effects. Inspired by fibrinogen binding to …
[PDF] archive.org

[PDF][PDF] Fibrinogen-mimicking, multiarm nanovesicles for human thrombus-specific delivery of tissue plasminogen activator and targeted thrombolytic therapy

Y Huang, B Gu, II Salles-Crawley, KA Taylor, L Yu… - 2021 - scholar.archive.org
Clinical use of tissue plasminogen activator (tPA) in thrombolytic therapy is limited by its
short circulation time and hemorrhagic side effects. Inspired by fibrinogen binding to …

Fibrinogen-mimicking, multiarm nanovesicles for human thrombus-specific delivery of tissue plasminogen activator and targeted thrombolytic therapy

Y Huang, B Gu, II Salles-Crawley, KA Taylor… - Science …, 2021 - discovery.ucl.ac.uk
Clinical use of tissue plasminogen activator (tPA) in thrombolytic therapy is limited by its
short circulation time and hemorrhagic side effects. Inspired by fibrinogen binding to …
[HTML] nih.gov

[HTML][HTML] Fibrinogen-mimicking, multiarm nanovesicles for human thrombus-specific delivery of tissue plasminogen activator and targeted thrombolytic therapy

Y Huang, B Gu, II Salles-Crawley, KA Taylor… - Science …, 2021 - ncbi.nlm.nih.gov
Clinical use of tissue plasminogen activator (tPA) in thrombolytic therapy is limited by its
short circulation time and hemorrhagic side effects. Inspired by fibrinogen binding to …

Fibrinogen-mimicking, multiarm nanovesicles for human thrombus-specific delivery of tissue plasminogen activator and targeted thrombolytic therapy

Y Huang, B Gu, II Salles-Crawley… - Science …, 2021 - pubmed.ncbi.nlm.nih.gov
Clinical use of tissue plasminogen activator (tPA) in thrombolytic therapy is limited by its
short circulation time and hemorrhagic side effects. Inspired by fibrinogen binding to …
[PDF] sgul.ac.uk

[PDF][PDF] Fibrinogen-mimicking, multiarm nanovesicles for human thrombus-specific delivery of tissue plasminogen activator and targeted thrombolytic therapy

Y Huang, B Gu, II Salles-Crawley, KA Taylor, L Yu… - 2021 - openaccess.sgul.ac.uk
Clinical use of tissue plasminogen activator (tPA) in thrombolytic therapy is limited by its
short circulation time and hemorrhagic side effects. Inspired by fibrinogen binding to …